Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A new landmark study, which demonstrated it is possible to recruit large numbers of women into a clinical trial evaluating treatments for HIV infection, found no significant gender-based differences in response to the anti-HIV drugs darunavir and ritonavir — at least among those who remained in the trial to the end.
However, women dropped out of the Gender, Race and Clinical Experience study at higher rates than men for reasons other than drug failure, indicating that more must be done to retain women in clinical trials that shed important light on the effectiveness of drugs in development or those on the market.
The study, published in the September 21 issue of Annals of Internal Medicine, showed that nearly one third of women dropped out, compared with less than one-fourth of the men enrolled.
"It is critical that women are involved in clinical trials to evaluate the efficacy and toxicity of new treatment — not just for HIV but for all diseases," says Judith Currier, the study's lead author, who is a professor of medicine and chief of the division of infectious diseases at the David Geffen School of Medicine at UCLA. Currier is also codirector of the UCLA Center for Clinical AIDS Research and Education and a member of the UCLA AIDS Institute.
Conducted between October 6, 2006, and December 19, 2008, at 65 sites in the United States, Puerto Rico, and Canada, the study examined the drugs' effectiveness, their adverse effects, and tolerability in both men and women. The researchers recruited 429 HIV-positive subjects who had previously taken HIV therapy. Of the subjects, 287 (66.9%) were women and 142 (33.1%) were men. Overall, 84% were black or Hispanic. In most treatment studies of HIV medications, women account for less than 25% of participants.
The study participants received 600 milligrams of darunavir and 100 milligrams of ritonavir twice daily. In addition, etravirine, tenofovir, and emtricitabine were available for use as needed. Tibotec Therapeutics markets darunavir and etravirine, Abbot Laboratories markets ritonavir, and Gilead markets tenofovir and emtricitabine.
The percentages of women and men who were able to suppress the HIV virus during the study were generally similar. However, a significantly higher proportion of women than men discontinued the study (32.8% versus 23.2%).
When the researchers examined the treatment response of all the participants who entered the trial — including those who eventually dropped out — they found that response rates in women appeared lower than response rates in men (50.9% versus 58.5%). But this difference appeared to be due to the higher dropout rate among women. When they excluded participants who discontinued the study for reasons other than virologic failure, the response rates were similar in women and men (73% versus 73.5%).
Adverse side effects were also comparable between the sexes. For both women and men, the most common side effects — which were considered to be at least possibly related to the treatment — included nausea (5.2% of women, 2.8% of men), diarrhea (4.5% versus 4.9%) and rash (2.1% versus 2.8%).
"The GRACE study shows that it is possible to enroll large numbers of women into HIV treatment trials," the researchers conclude. "The higher discontinuation rate in women, which was driven by reasons other than virologic failure, highlights the need for additional efforts to retain diverse populations in studies."
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Plus: Featured Video
Latest Stories
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM